Compositions and methods for the treatment of juvenile neuronal ceroid lipofuscinosis and related disorders
US-2017049761-A1 · Feb 23, 2017 · US
Amphiphilic aminoglycoside connexin hemichannel inhibitors
US12286452B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12286452-B2 |
| Application number | US-202017119301-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 11, 2020 |
| Priority date | Jun 12, 2018 |
| Publication date | Apr 29, 2025 |
| Grant date | Apr 29, 2025 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention includes novel molecules and methods of using an amphiphilic kanamycin molecule having substitutions at the O-4″, O-6″, or O-4″ and O-6″ positions having reduced antimicrobial activity for targeting Connexin Hemichannels.
First claim
Opening claim text (preview).
What is claimed is: 1. An amphiphilic molecule with a structure having reduced antimicrobial activity when compared to unmodified kanamycin; wherein Y is H 2 , Z is HR 4 , R 1 , R 2 , R 3 , R 4 are, methyl, ethyl, propyl, butyl, linear alkyl, alkylcarbonyl chains, or cyclic groups. 2. The molecule of claim 1 , wherein the molecule has at least one of: substantially no antimicrobial activity, no antibacterial activity, or inhibits connexin hemichannels. 3. A molecule of formula: wherein R in compounds 7b to 7 h is selected from at least one of: R Compound 7b 7c 7d 7e 7f 7g 7h. 4. A molecule comprising the formula: wherein Code/compound # R K46B01/7 Benzyl; K46BM5/8 Benzyl and all hydroxyl groups were methylated; K46B09/10 K46B03/11 K46B10/12 K46B04/13 K46B05/14 K46B11/15 K46B07/16 5. A molecule having the formula:
Assignees
Inventors
Classifications
attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} · CPC title
Processes for the preparation of sugar derivatives · CPC title
- C07H15/234Primary
attached to non-adjacent ring carbon atoms of the cyclohexane rings, e.g. kanamycins, tobramycin, nebramycin, gentamicin A2 · CPC title
Drugs for disorders of the cardiovascular system · CPC title
Drugs for dermatological disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12286452B2 cover?
- The present invention includes novel molecules and methods of using an amphiphilic kanamycin molecule having substitutions at the O-4″, O-6″, or O-4″ and O-6″ positions having reduced antimicrobial activity for targeting Connexin Hemichannels.
- Who is the assignee on this patent?
- Univ Texas Tech System, Univ Utah, Univ Utah State
- What technology area does this patent fall under?
- Primary CPC classification C07H15/234. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).